OncoMatch/Clinical Trials/Osteosarcoma
Osteosarcoma Clinical Trials
OncoMatch filters Osteosarcoma trials by the molecular markers that determine eligibility — TP53, RB1, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaAbout Osteosarcoma trials
Osteosarcoma is the most common primary bone cancer in children and young adults, with a second smaller peak in older adults (often associated with Paget disease or prior radiation). TP53 and RB1 alterations are both very common in osteosarcoma and frequently arise as germline mutations: Li-Fraumeni syndrome (germline TP53) and hereditary retinoblastoma (germline RB1) both predispose to osteosarcoma. Germline evaluation is considered when age, personal history, family history, bilateral/multifocal disease, or prior retinoblastoma history suggests an inherited predisposition.
Osteosarcoma trial design begins with age, hereditary cancer syndrome status, and prior chemotherapy. Front-line trials in pediatric and adolescent / young adult (AYA) osteosarcoma run primarily through cooperative-group networks (Children's Oncology Group, EURAMOS), testing modifications to the MAP regimen (high-dose methotrexate, doxorubicin, cisplatin) and post-induction strategies. Relapse and refractory trials test novel mechanisms (RANKL inhibitors, GD2-targeted approaches, MET / IGF-1R inhibitors, IO combinations) because effective second-line options are limited. Pulmonary metastasectomy + systemic therapy combinations are an active research area because lung metastases are the most common site of relapse. Adult osteosarcoma trials are smaller in number and often run separately from pediatric / AYA cooperative-group studies.
Osteosarcoma trial coordinators typically ask about age, hereditary syndrome status, prior MAP exposure, and pulmonary metastasis status. Age cutoffs vary, with most pediatric and AYA trials enrolling up to 30 or 40 and adult trials enrolling separately. Germline testing status (for Li-Fraumeni or hereditary retinoblastoma) for hereditary-syndrome-specific trials. Prior chemotherapy exposure (MAP and ifosfamide-etoposide salvage) and lines define R/R trial eligibility. Surgical status of primary tumor resection (limb-salvage vs amputation, completeness) for trials testing post-surgical or organ-preserving strategies. Pulmonary metastasis status and resectability for trials that include locoregional pulmonary therapy. Performance status using Lansky for younger patients or Karnofsky / ECOG for older.
Top recruiting Osteosarcoma trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Children's Oncology Group
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
National Cancer Institute (NCI)
Use of GnRHa During Chemotherapy for Fertility Protection
Kenny Rodriguez-Wallberg
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
SPEARHEAD-3 Pediatric Study
USWM CT, LLC
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
How OncoMatch finds Osteosarcoma trials for you
AI reads the protocol
Every Osteosarcoma trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Osteosarcoma and mark your biomarker results — TP53, RB1 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.